Allie Nawrat

You can get in touch with Allie on Alexandra.Nawrat@verdict.co.uk

All articles by Allie Nawrat

  1. Pfizer and Astellas report OS data for Xtandi in non-metastatic CRPC

    Japanese company Astellas and US-headquartered Pfizer have announced final overall survival (OS) for Xtandi (enzalutamide) in non-metastatic castration-resistant prostate cancer…
    Read More…

    12 Feb
  2. Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer

    New Jersey-based Immunomedics has developed a novel antibody drug conjugate (ADC) platform centred around its specialised hydrolysable linker, which delivers…
    Read More…

    12 Feb
  3. Lilly and Genentech announce two failures in Alzheimer’s disease prevention study

    Eli Lilly has announced its drug solanezumab failed to meet its primary endpoint in the Phase II/III Dominantly Inherited Alzheimer…
    Read More…

    11 Feb
  4. Coronavirus outbreak: UK raises threat level as cases double to eight

    Coronavirus in the UK: Measures and impact 12 FEB Update: Nine schools in East Sussex test staff and pupils for…
    Read More…

    10 Feb
  5. Wuhan coronavirus an extremely serious threat to global health, Pharma Tech survey finds

    On the final day of 2019, authorities in Wuhan, Hubei province, China, reported a case of pneumonia with an unknown…
    Read More…

    10 Feb
  6. Study shows NK therapy is safer than CAR-T therapy

    A study led by researchers at the MD Anderson Cancer Centre has shown that Natural Killer (NK) cells that have…
    Read More…

    7 Feb
  7. Bridge Biotherapeutics in-licenses Konkuk University’s back eye disorder drug

    South Korea-based Bridge Biotherapeutics has acquired an early stage back eye disorder drug from Konkuk University for a total of…
    Read More…

    5 Feb
  8. NIAID terminates HVTN 702 HIV vaccine trial in South Africa

    Following recommendations from an independent data and safety monitoring board (DSMB), the National Institutes of Health’s (NIH) National Institute of…
    Read More…

    4 Feb
  9. Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Advanced technologies provider Catalent has acquired cell and gene therapy manufacturer MaSTherCell Global for $315m in cash. The transaction is…
    Read More…

    3 Feb
  10. Life sciences in 2030: predicting the future with the Pistoia Alliance

    How can pharma and life sciences be prepared and agile enough to respond to future challenges if it has not…
    Read More…

    3 Feb
Close
Close
Close

Go Top